Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization

NCT00681603 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Lipid Keratopathy
Penetrating Keratoplasty
Herpetic Keratopathy
Rosacea

Interventions

DRUG: subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)

Sponsor

National Taiwan University Hospital